Non-surgical treatment of hilar cholangiocarcinoma

Abstract

Cancer of the biliary confluence also known as hilar cholangiocarcinoma (HC) or Klatskin tumor, is a rare type of neoplastic disease constituting approximately 40%-60% of intrahepatic malignancies, and 2% of all cancers. The prognosis is extremely poor and the majority of Klatskin tumors are deemed unresectable upon diagnosis. Most patients with unresectable bile duct cancer die within the first year after diagnosis, due to hepatic failure, and/or infectious complications secondary to biliary obstruction. Curative treatments include surgical resection and liver transplantation in highly selected patients. Nevertheless, very few patients are eligible for surgery or transplant at the time of diagnosis. For patients with unresectable HC, radiotherapy, chemotherapy, photodynamic therapy, and liver-directed minimally invasive procedures such as percutaneous image-guided ablation and intra-arterial chemoembolization are recommended treatment options. This review focuses on currently available treatment options for unresectable HC and discusses future perspectives that could optimize outcomes.

Keywords: Ablation; Cholangiocarcinoma; Interventional radiology; Liver; Oncology; Radiotherapy.

Figure 1

The Habib™ EndoHPB bipolar radiofrequency catheter (Boston scientific).

Figure 2

Radiation treatment plan for a patient treated with stereotactic body radiotherapy for hilar cholangiocarcinoma. The plans show isodose levels in the axial plane, coronal plane, and sagittal plane. A: Axial plane; B: Coronal plane; C: Sagittal plane.